CellGenTech

Executive Summary

CellGenTech is a Japanese biotechnology company pioneering ex-vivo gene therapy through its proprietary GMAC (Genetically Modified Human Adipocytes) platform. The company engineers a patient's own fat cells to express therapeutic proteins, offering a one-time, potentially curative treatment for genetic disorders. CellGenTech's pipeline targets rare metabolic diseases such as familial LCAT deficiency and Fabry disease, as well as hemophilia A. Founded in 2020 and based in Yokohama, the company is currently in Phase 1 clinical development. Its platform aims to leverage the adipocyte's natural protein secretion capabilities to provide durable, systemic delivery of missing enzymes or clotting factors, addressing the underlying genetic defects with a single intervention.

Upcoming Catalysts (preview)

• Q3 2027Initial clinical data from Phase 1 trial for GMAC-LCAT (familial LCAT deficiency)45% success
• Q2 2027Regulatory approval from PMDA to initiate Phase 1 trial for GMAC-Fabry70% success
• 2027Partnership or licensing deal for GMAC platform in hemophilia A40% success